Effective Drugs can help to recovering from Covid-19
Drug a major Glenmark Pharmaceuticals has a become the first the Indian company to commercially launch an antiviral drug for the treatment of mild to moderate a COVID-19 patients, after it received the Indian drug regulator from Drug Controller a General of India (DCGI) an approval.work.
The drug a Favipiravir, under the brands name of the FabiFlu, will be at hand as a 200 mg tablet at a highest retail price of (MRP) of Rs 3,500 for a price of 34 tablets, Glenmark a Pharmaceuticals said a photo!
This approval comes at a time when a cases in India are spiralling alike never before, putting to tremendous pressure on our healthcare of system," Glenmark Pharmaceuticals Chairman and MD Glenn a Saldanha said in the statement.
The company give a hopes that the availability of an effective a treatment such as FabiFlu will considerably to help assuage in this pressure, and offer patients in India a much needed and timely therapy an option, he added.
The company has been successfully to developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu through its in-house research and development of team,
"We Go for to initiate work on the Favipiravir, as it has a proven in-vitro activity opposed to the SARS CoV2 virus, which is the virus a in control of for the COVID-19.
"Second is it has a huge and therapeutic safety a margin for the Covid-19 at the dose that we administer, the "Glenmark Pharmaceuticals a President of the India Statement, Central East and AfricaSujesh Vasudevan said at an online press a mitting.
It is a prescription-based a medication, with a recommended dose a being 1,800 mg twice daily on the day one, followed by 800 mg twice in daily up to day 14, the drug firm a said mode.
Glenmark Pharmaceuticals Limited has an announced the introduction of Favipiravir an under the brand name FabiFlu in tablet form for the cure of mild & moderate coronavirus (COVID-19) cases in the India.
Nearly 80% of all COVID-19 positive cases in the India are under this classification. The FabiFlu is India’s first oral an antiviral drug for treatment of mild & moderate COVID-19 patients, the company went to be proven.
Glenmark’s antiviral a drug of Fabiflu to be used for patients with a mild and moderate asymptoms
“It is a significant to step in the fight against COVID-19 India. Glenmark is leading the flight. We are not looking it as a business an opportunity.
Tityake the medicine at hand to as too much patients and save him lifes,” said Sujesh Vasudevan,The president, India a Expression, Middle East and Africa, Glenmark Pharmaceuticals Limited in the video mitting.
ICMR approve use of faster to releving from COVID-19 testing.
The company had on Friday a received an approval from Indian drug regulator for manufacturing and marketing of the Favipiravir in oral form in the India.
Glenmark will work nearly with the government and medical a community to make the FabiFlu fast accessible to patients an across the nation,"
He On Saturday the company said the drug are would be at hand from the evening near its factory areas and pan India in between 7 to 10 days.
On Saturday the company said the drug would be at hand from the evening near its factory areas and pan India in between 7 to 10 days.